Grifols (GRFS) Scheduled to Post Earnings on Tuesday

Grifols (NASDAQ:GRFSGet Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, May 14th.

Grifols Trading Up 3.1 %

Shares of Grifols stock traded up $0.22 during trading on Monday, hitting $7.22. 1,557,058 shares of the company were exchanged, compared to its average volume of 2,677,004. The company has a current ratio of 2.79, a quick ratio of 1.29 and a debt-to-equity ratio of 1.26. Grifols has a fifty-two week low of $5.30 and a fifty-two week high of $12.15. The firm has a 50 day moving average price of $6.54 and a 200 day moving average price of $8.20.

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft downgraded shares of Grifols from a “hold” rating to a “sell” rating in a research note on Tuesday, March 12th.

Read Our Latest Research Report on Grifols

About Grifols

(Get Free Report)

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

See Also

Earnings History for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.